STAT News

STAT+: Vertex kidney disease drug scrutinized for infection risk

Ahead of its FDA approval decision on Nov 30, Vertex's kidney disease drug is being heavily scrutinized for infection risk.

By STAT News

1 min read
STAT+: Vertex kidney disease drug scrutinized for infection risk
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights